As mentioned in Section 2, these biological aspects are needed while developing a mathematical model to represent the treatment scenario facilitated by a single agent (e.g., anti-HER2 alone) or multiple agents (e.g., anti-HER2 with immune checkpoint inhibition) for HER2+ BC. Here, ERBB2 is linked to breast cancer.